PTBP1 and cholangiocarcinoma: For example, HNRNPK has been shown to be a therapeutic target for cholangiocarcinoma [33] and cervical cancer [34]; the expression of HNRNPI [35] has been shown to influence the development of colitis into colorectal cancer; and in liver cancer, HNRNPA1 [36] has been shown to affect patient prognosis, while HNRNPAB [37] promotes metastasis.